Replies to post #119057 on Biotech Values

[DewDiligence]

REGN—This current study is something of a hybrid - there were monthly appointments and scans, and treatments when needed.

In the real world, Lucentis patients see the eye doctor when they get treated—rarely, if ever, between treatments, as REGN alleges. I’m surprised that you’re falling for REGN’s spin that Trap is significantly more convenient than Lucentis. In fact, after the initial loading period, there is essentially no difference between the two drugs in convenience.